Yoshinori Ito
Experienced in Laryngeal Cancer

Yoshinori Ito

Tokyo, JP 
Experienced in Laryngeal Cancer
Tokyo, JP 
OverviewLocationsClinical Research

Overview

Yoshinori Ito practices in Tokyo, Japan. Mr. Ito is rated as an Experienced expert by MediFind in the treatment of Laryngeal Cancer. His top areas of expertise are Esophageal Cancer, Breast Cancer, Mononucleosis, Mastectomy, and Endoscopy.

His clinical research consists of co-authoring 568 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 5 articles in the study of Laryngeal Cancer.

Gender
Male

Locations

Tokyo, Japan
Other Locations
Nagakute, Japan
3191195, Japan
Tokai, 3191195, Japan
Takaidonishi, 1688535, Japan
Kahoku, 9200293, Japan
Hatanodai, 1428666, Japan
Nagoya, Japan
Ichinomiya, Japan
Nara-shi, 6308506, Japan
Itabashi, 1738610, Japan
Okazaki, Japan
Ariake, 1358550, Japan
Takatsuki, Japan
Kurokami, 8608555, Japan
Chuo, 1040045, Japan
Tokai, 3191195, Japan
Yokohama, 2270043, Japan
Karatsu, 8478588, Japan
Tsukiji, 1040045, Japan
Wako, 3510198, Japan
Okayama, Japan
Toyohashi, 4418580, Japan
Sendai, 9808577, Japan
Kobe, 6500011, Japan
Gifu-shi, Japan
Sayo, 6795148, Japan
Kurashiki, Japan
Shinjuku, 1631328, Japan
Fuchu, 1838509, Japan
Saitama, Japan
Osaka, Japan
Chuo, Japan
Hibarigaoka, 4418580, Japan
Shibuya, 1508935, Japan
Kashiwa, 2778581, Japan
Oita, Japan
Shiba, Japan
Toshima, 1708455, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3

567 Total Publications

Emerging Radiotherapy for Esophageal Cancer
Emerging Radiotherapy for Esophageal Cancer
Journal: Gan to kagaku ryoho. Cancer & chemotherapy
Published: January 19, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Ito's expertise for a condition
ConditionClose
View All 17 Advanced Conditions
View All 113 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile